Raymond James raises UnitedHealth stock price target on clean quarter

Raymond James raised its UnitedHealth price target to $370 from $330 and reiterated an Outperform rating, citing a cleaner quarter and improving fundamentals in the insurance business. The article also highlights Q1 2026 results with adjusted EPS of $7.23 versus $6.57 consensus and revenue of $111.7 billion versus $109.2 billion expected, while noting upside from Medicare/Optum Health stabilization and AI-driven cost efficiencies. Multiple other firms also raised targets after the earnings beat, reinforcing a constructive outlook for UNH.

Analysis

UNH is transitioning from a multiple-compression story to a self-help + estimate-revision story, and that matters more than the headline price target. The key second-order effect is that once a large-cap managed care name is viewed as “stabilizing,” the market stops pricing permanent impairment in Medicare Advantage and Optum and starts underwriting a normal margin path again; that can drive a step-function re-rating over the next 1-2 quarters if subsequent prints stay clean. The AI cost-takeout angle is also important: even modest administrative efficiency gains can have outsized EPS leverage in a business where small changes in medical cost trends move earnings materially.

The biggest winner is not just UNH stock, but the broader healthcare complex’s risk premium. If this earnings season is interpreted as proof that utilization and pricing pressure are peaking, then investors will be more willing to underwrite other payers and outsourced healthcare services with less fear of a sector-wide earnings reset. That said, the reversal risk is asymmetric: Medicare Advantage and Optum-related optimism can unwind quickly if utilization inflects again, and any evidence that AI savings are slower to monetize than expected would force the street to cut 2027 estimates, which is where much of the upside is being implicitly pulled from.

The consensus may be underestimating how much of this move is already about positioning, not fundamentals. A 10% weekly move in a mega-cap usually forces systematic buying and short covering, so the near-term trade is more about flows than valuation. If the next catalyst is simply another “not bad” quarter, the stock can grind higher; if there is any disappointment in medical cost ratio or guidance cadence, the stock likely de-rates sharply because expectations have shifted from survival to acceleration.

Key Decisions for Investors

• Go long UNH on pullbacks over the next 1-3 weeks, targeting a re-rating toward the next sell-side cluster; use a tight stop below the post-earnings breakout area because the trade is now sentiment-sensitive, not valuation-only.
• Buy UNH Jan/Mar call spreads rather than outright stock to capture further estimate revisions with defined downside; best setup is if the name consolidates after the recent squeeze and implied volatility cools.
• Pair long UNH vs short a basket of lower-quality managed care / health services names for 1-3 months, on the view that investors will reward balance-sheet and execution clarity while punishing names still in the “prove it” stage.
• Fade the move only if the next monthly/quarterly utilization data shows re-acceleration; in that case, short UNH on a failed breakout with a 2-4 week horizon because the stock is now vulnerable to de-rating from elevated expectations.
• Use any continued strength in UNH as a signal to add exposure to the broader healthcare bucket selectively, but avoid chasing less liquid peers until there is confirmation that this is a sector-wide margin stabilization and not company-specific relief.